Reiser M, et al. - Rituximab-containing chemoimmunotherapies have become the standard of care for chronic lymphocytic leukaemia (CLL), particularly for physically fit patients. In this current investigation, chemoimmunotherapy with rituximab was shown to be feasible as well as safe in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities.